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Abstract
Oxidative stress is involved in the pathogenesis of Duchenne muscular dystrophy (DMD), an X-linked genetic disorder caused
by mutations in the dystrophin gene and characterized by progressive, lethal muscle degeneration and chronic inflammation.
In this study, we explored the expression and signaling pathway of a master player of the anti-oxidant and anti-inflammatory
response, namely NF-E2-related Factor 2, in muscle biopsies of DMD patients. We classified DMD patients in two age groups
(Class I, 0–2 years and Class II, 2–9 years), in order to evaluate the antioxidant pathway expression during the disease progres-
sion. We observed that altered enzymatic antioxidant responses, increased levels of oxidized glutathione and oxidative damage
are differently modulated in the two age classes of patients and well correlate with the severity of pathology. Interestingly, we
also observed a modulation of relevant markers of the inflammatory response, such as heme oxygenase 1 and Inteleukin-6 (IL-
6), suggesting a link between oxidative stress and chronic inflammatory response. Of note, using a transgenic mouse model, we
demonstrated that IL-6 overexpression parallels the antioxidant expression profile and the severity of dystrophic muscle ob-
served in DMD patients. This study advances our understanding of the pathogenic mechanisms underlying DMD and defines
the critical role of oxidative stress on muscle wasting with clear implications for disease pathogenesis and therapy in human.
Introduction
Increasing evidence shows that oxidative stress is involved in
the pathogenesis of Duchenne muscular dystrophy (DMD), an
X-linked genetic disorder caused by mutations in the dystro-
phin gene (1,2). Loss of the sarcolemmal integrity by the absence
of the dystrophin protein, in both humans and mdx mouse
model, leads to a cascade of pathological events that cause
muscle fiber degeneration.
Altered enzymatic antioxidant responses, increased levels of
oxidized glutathione and enhanced protein oxidation have been
reported in mdx mice and in muscle biopsies of DMD patients
(3–5). A role for oxidative stress in DMD is further supported by
pre-clinical studies performed on mdx mice that report benefits
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(improved muscle pathology, decreased necrosis) for many anti-
oxidant drugs (coenzyme Q10, catalase, green tea extracts, res-
veratrol, N-acetylcysteine) (6–17), and on patients with DMD not
using glucocorticoids (18–20). A double-blind randomized
placebo-controlled phase 3 trial showed that the short-chain
benzoquinone idebenone significantly reduced the loss of respi-
ratory function in patients with DMD, suggesting this drug as a
suitable treatment option to ameliorate a life-threatening com-
plication of the disease (20). However, the efficacy of antioxi-
dants in clinical trials has to be fully elucidated; thus
monitoring glutathione systemic levels and understanding the
precise sequence of events deriving from oxidative stress in
DMD could be certainly useful.
Glutathione (c-glutamyl-cysteinyl-glycine; GSH) is the most
abundant low-molecular-weight thiol, and GSH/glutathione di-
sulfide (GSSG) is the major redox couple in animal cells. The
synthesis of GSH from glutamate, cysteine and glycine is cata-
lyzed sequentially by two cytosolic enzymes, c-glutamylcys-
teine synthetase and GSH synthetase. Compelling evidence
shows that GSH synthesis is regulated primarily by c-glutamyl-
cysteine synthetase activity, cysteine availability and GSH feed-
back inhibition (21).
In order to shed light on the cascade of events triggered by
oxidative stress, we analyzed the most important redox-
activated pathway in muscle biopsies obtained from 11 children
with DMD. This study moves from recent papers that recognize
NF-E2-related Factor 2 (NRF2) as an important player in the
anti-oxidant and anti-inflammatory response in dystrophin-
deficient mice (22,23).
NRF2 is an inducible transcription factor that, in response to
oxidative stress, regulates the expression of phase II enzyme
genes by interacting with the antioxidant responsive element
(ARE) sequence (24–26). Under normal condition, NRF2 is se-
questered in cytoplasm and its activity is regulated by Kelch
ECH associating protein 1 (KEAP1) through the complex KEAP1-
NRF2, which promotes the ubiquitination and degradation of
NRF2. Upon exposure to several stressors (environmental
agents, endogenous inducers, drugs), NRF2 is released and
translocates in the nucleus where its antioxidant functions oc-
cur (26–28).
Several genes are target for NRF2: those involved in glutathi-
one synthesis, such as the glutamate-cysteine ligase (GCL),
those implicated in the detoxification of xenobiotics, including
the NAD(P)H quinone dehydrogenase 1 (NQO1) and the heme
oxygenase 1 (HO-1), and the genes involved in the neutraliza-
tion of reactive oxygen species (ROS) (Superoxide Dismutase,
SOD) (24,25,29).
Given that previous studies have identified NADPH oxidase
(NOX)-dependent ROS production and NRF2 activation as
mainly responsible for the enhanced susceptibility to injury in
dystrophin-deficient heart and skeletal muscle (30,31), the aim
of this study was to explore the NRF2 expression and its signal-
ing pathway in muscle biopsies of children with DMD.
Moreover, in light of previous data showing a decrease in redox
related genes in DMD, we also investigated HO-1, NQO-1 and
SOD expression in DMD muscle biopsies. Importantly, since
ROS levels appear progressively and temporally enhancing in
dystrophic mouse models (32,33), we classified our patients in
two age groups, in order to evaluate the antioxidant pathway
expression during the disease progression. Finally, as pharma-
cological antioxidant approaches showed effects in reducing
the pathogenic progression of the muscular dystrophies (34), we
also wanted to assess the levels of two critical markers of sys-
temic oxidative stress: the oxidized and reduced forms of
glutathione (GSSG/GSH ratio) and the carbonyl content, indica-
tive of the irreversible oxidative damage to proteins. Overall in
this study, we focus on the redox signaling pathway of NRF2 in
human DMD, attempting to address additional targeted phar-
macological approaches.
Results
Analysis of local (muscle) oxidative stress in DMD
In order to correlate the oxidative stress response with the pro-
gression of the disease, we subdivided the DMD patients
into two groups, namely Class I (0–2 years) (n¼ 6) and Class II
(2–9 years) (n¼ 5) children, according to the age at the biopsy. Of
note, none of the participants at the time of biopsy collection
was under corticosteroid treatment.
NAPDH oxidase 2 (NOX2) has a central role in the pathology
of DMD as source of ROS (35–37), thus we examined the ex-
pression of the NOX2 catalytic subunit (gp91-phox) on muscle
biopsies of 11 patients. As reported in Fig. 1A, the qRT-poly-
merase chain reaction (PCR) analysis showed a significant in-
crease of NOX2 gene expression in both groups of patients
compared with age-matched controls (5.5-fold Class I, 5.7-fold
Class II).
Moving from the evidence that NOX-dependent ROS has
been shown to activate the NRF2 redox signaling pathway (38),
we analyzed the expression of NRF2 and its target genes by
qRT-PCR and western blotting. NRF2 gene expression was sig-
nificantly increased in both age groups of patients, compared
with controls (Fig. 1B), although the activation appeared less
pronounced in patients of Class II (3.3-fold increase in Class I,
1.9 in Class II). Western blot analysis confirmed the significant
increase of NRF2 protein amount in younger patients (66%)
compared with age matched controls, whereas in Class II it fell
to levels comparable to those of age-matched controls (Fig. 1C).
To note, when compared Class II with Class I patients a consis-
tent reduction of NRF2 protein levels was observed (Fig. 1C),
suggesting an impairment of the antioxidant compensatory
mechanism during the progression of pathology.
To examine if the NRF2 activation up-regulated phase II en-
zymes genes, we evaluated the expression of NQO1, the enzyme
catalyzing the reduction of quinones to hydroquinones,
Superoxide dismutase (MnSOD, CuZnSOD) that functions as
scavenger of ROS, and HO-1, which is protective against early
phases of inflammation. As reported in Fig. 2A, expression of
these genes significantly increased in muscle of both classes of
patients, especially NQO1 (6.2-fold increase in Class I and
1.7-fold in Class II) and HO-1 (6.9-fold in Class I and 5.5-fold in
Class II). Furthermore, SOD1 and SOD2 mRNA significantly in-
creased, but the increments were comparable in both classes
compared with age-matched controls (SOD1, 2.7-fold in Class I,
2.3-fold in Class II; SOD2, 2.9 in Class I, 2.1 in Class II).
Western blot analysis confirmed the high protein levels of
NQO1 in Class I (85% increase) and the slight increase in pa-
tients of Class II (Fig. 2B). Conversely HO-1, whose gene expres-
sion consistently increased in both classes, significantly
decreased in Class I patients and remained at levels of controls
in Class II DMD (Fig. 2C). These results are quite surprising,
given the protective role of HO-1 against the immune-mediated
tissue injury (39). Therefore, as it has been shown that HO-1 de-
ficiency causes chronic inflammation (40,41), we measured the
amount of Inteleukin-6 (IL-6), a key mediator of chronic inflam-
mation (42), in muscle of DMD patients. As showed in Fig. 2D,
the IL-6 mRNA expression was significantly increased in both
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groups of age, although more consistent in the children of Class
I (6.3-fold in Class I; 2.1-fold in Class II).
These findings are in agreement with previous observations,
in both humans and mice, where the up-regulation of inflam-
matory molecules, in particular IL-6, was reported in DMD and
mdx muscles (43,44).
To support the link between oxidative stress and chronic in-
flammatory response mediated by IL-6, we analyzed relevant
markers of oxidative stress in a recent generated animal model,
namely mdx/IL6, in which increased levels of IL-6 exacerbate
the dystrophic muscle phenotype, sustaining inflammatory re-
sponse and repeated cycles of muscle degeneration and regen-
eration, leading to exhaustion of satellite cells (45). Of note, IL-6
overexpression paralleled the human antioxidant expression
profile, upregulating several antioxidant genes, such as Nqo1,
Ho-1 and Sod1, in mdx mice (Fig. 3A). Moreover, the expression
of Nrf2 and Nox2 proteins was significantly increased in mdx/
IL6 mice compared with mdx littermates, similarly to the ex-
pression pattern observed in human DMD patients (Fig. 3B-C).
Muscle glutathione status in DMD
As NRF2 modulates the antioxidant response mainly inducing
the expression of the c-GCL gene, the rate-limiting enzyme of
the de novo glutathione synthesis, we evaluated if the activation
of NRF2 may have an impact on the muscle glutathione status.
As expected, a significant increase of mRNA GCL gene expres-
sion in both DMD age groups was obtained (3.9-fold in Class I,
4.2-fold in Class II, Fig. 4A). However, this gene induction was
not followed by a corresponding increase of tissue GSH levels,
whose local concentration was reduced in both classes, com-
pared with controls, and it was 38% lower in Class I patients
with respect to Class II (Fig. 4B).
Similarly to patients, we observed an increase of Gcl mRNA
expression (2.1-fold, Fig. 4C) and a decrease of GSH levels (32%,
Fig. 4D) in the muscles of 4-week old mdx/IL6 mice, compared
with mdx littermates.
Collectively, these findings demonstrate a local response to
oxidative stress by the activation of NRF2 redox pathway that,
however, does not appear to fully compensate the muscle redox
imbalance.
Analysis of systemic oxidative stress in DMD patients
In order to evaluate whether muscle oxidative imbalance was
correlated to the systemic oxidative stress, we measured GSH
levels in whole blood of DMD patients (Fig. 5). In agreement
with the GSH decrement observed in muscle, a significant GSH
decrease was found in blood of both Classes (Fig. 5A, 22% decre-
ment in Class I, 21% in Class II). Accordingly, a consistent in-
crease of GSSG was evidenced in both classes (Fig. 5B), leading
to a significant imbalance of the GSSG/GSH ratio (Fig. 5C).
GSH is the co-factor of many glutathione-dependent en-
zymes, thus we also determined the activity of the glutathione
peroxidase (GPx) enzyme in blood of patients (Fig. 5D). A signifi-
cant decrease of GPx activity in both Class I (18%) and Class II
(26%) patients was obtained, with respect to age-matched con-
trols. In addition, a marked protein carbonylation was further
detected in plasma of both classes of children with DMD (51%
increase in Class I, 48.5% 1 in Class II, Fig. 5E), evidencing oxida-
tive protein dysfunction in this disease. Indeed, protein carbon-
ylation, caused by the insertion of carbonyl groups into amino
acid residues, irreversibly modifies the protein structure, mak-
ing proteins not functional and causing cell and tissue dysfunc-
tion (46,47). Carbonyls content is a hallmark of oxidative
damage and its increase in plasma of our patients is strongly
suggestive of systemic oxidative stress. Moreover, despite the
well-known role of carbonylated proteins as redox markers, the
carbonylation of specific muscle proteins could have an addi-
tional significance in DMD, by contributing to muscle dysfunc-
tion, and further exacerbating the pathological context.
Discussion
Because of their contractile activity and their high oxygen con-
sumption and metabolic rate, skeletal muscles continuously pro-
duce moderate levels of ROS, which are buffered by multiple
antioxidant systems to maintain redox homeostasis. NOX is
Figure 1. Redox status in muscle of DMD patients. (A and B) Real time PCR analysis performed on biopsies of DMD patients (n¼11) and control subjects (Ctrls) for the ex-
pression of NOX2 (A) and NRF2 (B) mRNA. (C) Representative western blot (left panel) and densitometry (right panel) for NRF2 protein levels. Values represent
mean6SEM. *P<0.05, *** P<0.001; ## P<0.01 by Student’s two-tailed t test. Class I and II gels were simultaneously run under same experimental conditions.
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critical for the generation of ROS in muscle, and previous
studies have demonstrated a dramatic enhancement of NOX2-
dependent ROS production in dystrophin-deficient heart and
skeletal muscle (30,32). To note, the pharmacological decrease of
NOX2 expression significantly improved muscle function in the
mdx mouse model protecting from tissue damage and inflamma-
tion (48). In this study, we analyzed NOX gene expression in
muscle biopsies of 11 patients with DMD. Furthermore, as an age-
related progressive increase of oxidative stress has been shown
in dystrophic animals (32,33), we divided our patients into two
age classes: the Class I (0–2 years) and Class II (2–9 years).
According to the literature on mouse models, we found a progres-
sive increase of NOX gene expression in muscles from both
groups of patients, followed by a significant increase of NRF2
gene expression that was more evident in the Class I patients.
Unlike on mouse models, we found a similar increase of
NOX gene expression in muscles from both groups of patients,
followed by a significant increase of NRF2 gene expression that
was more evident in the Class I patients. This is confirmed by
NRF2 protein levels showing a consistent increase in the
0–2 years patients, whereas in Class II it fell to levels comparable
to those of age-matched controls. Indeed, the increase of NRF2
gene expression, although occurring in all patients, failed to ac-
tivate some genes encoding phase II detoxifying enzymes in
older patients. In particular, NQO1, which is highly expressed in
the Class I patients appears to slow down its antioxidant buffer-
ing activity in the children of Class II. NQO1 catalyzes the reduc-
tion of quinone to hydroquinone, thus preventing the toxic
accumulation of quinone products that bind to cellular nucleo-
philes, including the reduced form of glutathione, causing cellu-
lar damage (49,50). Therefore, the decreased NQO1 expression
in older patients may lead to accumulation of quinones, GSH
depletion and contribute to induce further generation of ROS in
DMD muscles.
Conflicting with the increased levels of NQO1, the amount of
HO-1 protein appears down-regulated in the Class I patients
Figure 2. NRF2-dependent antioxidant response in muscle of DMD patients. (A) Real time PCR analysis of NRF2-downstream genes (NQO1, HO-1, SOD1 and SOD2) on bi-
opsies of DMD patients (n ¼11). (B and C) Representative western blots (right panel) and densitometric analysis (left panel) of NQO1 (B) and HO-1 (C) protein levels.
(D) Real time PCR analysis for the expression of IL-6 on muscles of DMD patients. Values represent mean6SEM. *P<0.05, **P<0.01, ***P<0.001 respect to controls;
#P<0.05, ##P<0.01 compared with Class I. Class I and II gels were simultaneously run under same experimental conditions.
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(46% decrease), with respect to Class II, and this decrease could
explain abnormalities in inflammatory responses occurring
early in DMD. HO-1, the rate-limiting enzyme of heme degrada-
tion, plays a pivotal role in the early phases of immune re-
sponse and its impairment can determine the fate of
downstream events in the dystrophic muscle (40). Its protective
role in modulating the immune response has been demon-
strated in HO-1 knockout mice, where high levels of pro-
inflammatory cytokines [especially IL-1, IL-6 and tumor necrosis
factor (TNF-a)] were observed (40). Our findings show a 50% re-
duction of HO-1 protein in Class I patients, with respect to con-
trols, thus suggesting that the beneficial anti-inflammatory
effect of the enzyme does not fully occur in the younger chil-
dren. This partial HO-1 deficiency is associated with a consis-
tent up-regulation of IL-6 in Class I patients (6-fold increase,
while to 2-fold increase in Class II) and can predispose to an ex-
cessive inflammatory response or to delay the resolution of the
early inflammation.
To support these evidences we made use of a novel dystro-
phic animal model we recently generated, namely the mdx/IL6
mice, which closely approximates the human disease and more
faithfully recapitulates the disease progression in humans (45).
Indeed, we revealed both an enhanced oxidative stress and a
decrease of the antioxidant-compensatory mechanism during
the progression of pathology in mdx/IL6 mice, paralleling hu-
man DMD.
This evidence indicates that chronic inflammatory response
further exacerbates the dystrophic phenotype impinging the
anti-oxidant defense. The existence of a molecular borderline
between the ‘presymptomatic’ phase of the disease and the
later stage of DMD suggests that a pharmacological approach,
specifically acting in the presymptomatic phase of the pathol-
ogy, should ameliorate the efficacy of later therapeutic inter-
ventions on DMD patients.
A combined impairment of HO-1 in younger children and of
NQO1 in older patients may contribute to the early-onset of the
inflammation and to the progressive increase of ROS
production.
The temporal progression of muscle oxidation has been re-
ported in dysferlin-deficient muscle and in aged mdx mice (32),
where an amplified ROS signaling was also found (33,51).
Therefore, an efficient and long-term active antioxidant system
is critical to guarantee a prompt and stable response against the
increasing ROS production in DMD.
The essential contribution of NRF2 in the antioxidant re-
sponse derives also from its ability to modulate the expression
of the rate-limiting enzyme GCL, which is responsible of the
de novo synthesis of glutathione (26). Glutathione is the major
tissue redox buffer and it is a good indicator of the cellular redox
environment, as it promptly responds to redox fluctuations (52).
Indeed, the cellular redox balance is warranted by equilibrated
ratios among reduced (GSH) and oxidized (GSSG) glutathione
forms. Under physiological conditions, GSH normally exceeds
GSSG, but a slight increase of GSSG level is enough to dramati-
cally alter GSSG/GSH ratio thus triggering oxidative stress (53).
Therefore, the GSSG/GSH couple may be considered the most
important redox control node in redox homeostasis (54).
In our patients, we observed a significant increase of GCL ex-
pression in both age classes, indicating a consistent effort of the
muscle tissue in buffering the redox imbalance. However, as the
GSH is synthesized, it is promptly converted to GSSG or used as
a co-factor for the GPx enzyme, further perturbing the GSSG/
GSH ratio. Nevertheless, this antioxidant effort is not enough to
counteract oxidative stress in DMD, as demonstrated by the sig-
nificant increase of plasma carbonyls in our patients. However,
while the correlation between protein carbonylation and oxida-
tive stress is widely recognized, more studies are needed to bet-
ter understand the role of protein carbonylation in the etiology
of DMD, also considering that a role for protein carbonyls has
been reported in the activation of NRF2 signaling pathway (55).
Recently, NOX-mediated oxidative stress has been shown to
reduce autophagy in the mdx mouse (56). Although we do not
have a conclusive link between severity of pathology and
autophagy impairment we observed a reduction in the microtu-
bule-associated protein light chain (LC3) II/I levels in Class 2
DMD muscles, leading to tentatively hypothesize an impair-
ment of autophagy in the disease (data not shown). Additional
work will clarify the potential involvement of autophagy in
DMD pathogenesis.
Overall, our study confirms a central role for NRF2 in the
pathogenesis of DMD and, at the same time, shows a weakening
of the antioxidant response along the disease progression.
Our work is consistent with a model (Fig. 6) in which the ab-
sence of dystrophin expression activates an anti-oxidant path-
way to cope with the toxic effects induced by oxidative stress.
Nevertheless, the decrease of HO-1 protein levels, concomi-
tantly with an increase of IL-6 expression, impinge upon the ac-
tivation of a compensatory mechanism and promote the
establishment of a chronic inflammation, leading to exacerba-
tion of the dystrophic phenotype.
Figure 3. IL-6 overexpression parallels the human antioxidant expression profile
in mdx mice. (A) Real time PCR analysis performed on diaphragm muscles from
wild-type (WT), mdx and mdx/IL6 mice at 4 weeks of age, for the expression of
Nqo1, Ho-1, Sod1 and Sod2. Values are reported as fold change in expression rel-
ative to calibrator (WT, horizontal dot-line) and represent mean6SEM; n¼4–5
mice per group. *P<0.05 compared with mdx mice (by ANOVA with Bonferroni
correction). (B and C) Western blot analysis (bottom panel shows a representa-
tive image) for Nrf2 (B) and Nox2 (C) proteins, performed on diaphragm of
4-week-old mdx and mdx/IL6 mice. Values represent mean6SEM; n¼4–6 per
group. P value using Student’s two-tailed t test. In (B and C), the lanes were run
on the same gel but were not contiguous.
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The encouraging element deriving from this and other stud-
ies is that oxidative stress is a drug-targetable condition, thus
paving the way for the implementation of pharmacological tri-
als using NRF2 inducers and redox drugs already clinically ap-
proved for other diseases (57,58).
Materials and Methods
Patients
This study was performed on 11 genetically confirmed DMD pa-
tients (mean age 6 years, age range 0–9 years) followed at the
Unit of Neuromuscular Diseases at the Bambino Gesu
Children’s Hospital. In order to correlate the variability in the
antioxidant response with the progression of the disease, our
cohort of patients was subdivided into two groups, named Class
I (0–2 years) (n¼ 6) and Class II (2–9 years) (n¼ 5) children, ac-
cording to the age at the biopsy. Muscle biopsy samples were
collected at the time of diagnosis. Control biopsies (n¼ 3 aged-
matched for each group of patients) were from individuals in
whom a neurological diseases was suspected, but did not show
any sign of muscle pathology on histology and biochemical ex-
aminations. None of the participants at the time of biopsy or
blood collection was under corticosteroid treatment. The local
ethics committee approved the study and informed consent
was obtained from all subjects.
Figure 5. Systemic oxidative stress in DMD patients. GSH (A), GSSG (B), GSSG/GSH ratio (C), GPx activity (D) and protein carbolyls content (E) were measured in whole
blood of patients, as described in Materials and Methods. Values represent mean6SEM. *P<0.05, ***P<0.001, respect to controls (by Student’s two-tailed t test).
Figure 4. Muscle glutathione status in DMD. (A) The expression of GCL gene, the rate-limiting enzyme of the de novo glutathione synthesis, was analyzed by Real time
PCR in DMD patients (n¼11). (B) The GSH muscle concentration in DMD patients (n¼11) was measured by the enzymatic re-cycling assay. Values represent
mean6SEM; *P<0.05, ***P<0.001 respect to controls (Ctrls); ##P< 0.01 compared with Class I (by Student’s two-tailed t test). (C) Real time PCR analysis for the ex-
pression of GCL in diaphragm of 4-week-old WT, mdx, and mdx/IL6 mice. Values are expressed as the fold change relative to calibrator (WT, horizontal dot-line) and
represent mean6SEM; n¼4–12 mice per group. *P<0.05 compared with mdx (by ANOVA with Bonferroni correction). (D) Measurements of GSH in gastrocnemius of
4-week-old WT, mdx and mdx/IL6 mice. Values represent mean6SEM; n¼3 per group. *P<0.05, **P<0.01; #P<0.05 by Student’s two-tailed t test.
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Mice
Wild-type C57Bl/6J mice, mdx (Jackson Laboratories) and mdx/
IL6 (45) mice of 4 weeks of age used in the current study were
maintained according to the institutional guidelines of the ani-
mal facility of the unit of Histology and Medical Embryology. All
animal experiments were approved by the ethics committee of
Sapienza University of Rome-Unit of Histology and Medical
Embryology and were performed in accordance with the current
version of the Italian Law on the Protection of Animals.
Blood sample collection
Blood samples from 11 patients, obtained early after diagnosis
during routine analysis performed before the beginning of ste-
roid treatment, were collected into 5% ethylenediaminetetra-
acetic acid (EDTA) Vacutainer Tubes (Becton Dickinson,
Rutherford, NY, USA) to evaluate GSH and antioxidant enzyme
(GPx), or in Vacutainer Tubes prefilled with both EDTA and
N-ethylmaleimide (NEM, 30 mM final concentration, Sigma-
Aldrich, St. Louis, MO, USA) for GSSG determinations. Whole
blood was centrifuged at 450g for 3 min, to separate plasma
from erythrocytes. For carbonyl content analysis, plasma was
rapidly removed by aspiration and stored at 80 C until
analysis.
Quantitative real-time PCR
Total mRNA from muscle biopsy of patients and three age-
matched healthy controls was isolated using TRI Reagent
(Sigma-Aldrich), according to the manufacturer’s protocol. One
microgram of each RNA samples was reverse transcribed with
the SuperScriptTM First-Strand Synthesis system and random
hexamers as primers (Life Technologies, Carlsbad, CA, USA).
The expression levels of NRF2, GCL, HO-1, SOD1 and 2, NQO1,
IL-6 were measured by quantitative Real-Time PCR (qRT-PCR) in
an ABI PRISM 7500 Sequence Detection System (Life
Technologies, Carlsbad, CA, USA) using Power SYBR Green I dye
chemistry. Data on the expression levels of NOX2 were obtained
using a TaqManTM Universal PCR Master Mix and the appropri-
ate Assay-on-DemandTM Gene Expression Mix (Hs00166163 m1)
(Life Technologies). Data were analyzed using the 2-DDCt
method with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as housekeeping gene and data are shown as fold
change relative to control. Notably, the use of alternative
housekeeping genes, such as TATA box binding protein (TBP)
and glucuronidase beta genes did not modified the data ob-
tained with GAPDH gene. Total mRNA from diaphragm muscle
of wild-type, mdx and mdx/IL6 mice was extracted in TRI
Reagent (Sigma-Aldrich) using Tyssue Lyser (Quiagen). One mi-
crogram of each RNA sample was reverse transcribed using the
QuantiTect Reverse Transcription kit (Qiagen). Quantitative
Real-Time PCR was performed on an ABI PRISM 7500 SDS
(Applied Biosystem) using specific premade TaqMan assays for
Ho-1, Nqo1, Sod1, Sod2, gcl and hypoxanthine guanine phos-
phoribosyl transferase as housekeeping gene (Applied
Biosystem). Data were analyzed using the 2-DDCt method and
reported as mean fold change in gene expression relative to
wild-type.
Western blot analysis
Muscle samples were homogenized and lysed on ice with RIPA
buffer, including dithiothreitol (DTT) and protease inhibitors.
For western blotting analysis, 40 lg of proteins were subjected
to SDS PAGE on 4–12% denaturing gel and probed with the fol-
lowing antibodies: NRF2 (1:500, Abcam, Cambridge, UK), NQO1
(1:500, Novus Biologicals, Minneapolis, USA), HO-1 (1:2000,
Abcam, Cambridge, UK) and GAPDH (1:15000, Sigma-Aldrich) as
loading control. Immunoreactive bands were detected using the
Lite Ablot Extend Long Lasting Chemiluminescent substrate
(Euroclone, MI, Italy). Densitometric measurements were per-
formed using ImageLab Software (BioRad, Hercules, CA, USA).
Diaphragm muscles from 4-week-old mdx and mdx/IL6 mice
were homogenized in lysis buffer [Tris–HCl, pH 7.5/20 mM,
EDTA/2 mM, ethylene glycol tetraacetic acid/2 mM, sucrose/
250 mM, DTT/5 mM, Triton-X/0.1%, phenylmethylsulfonyl fluo-
ride (PMSF)/1 mM, sodium fluoride (NaF)/10 mM, sodium ortho-
vanadate (SOV4)/0.2 mM, cocktail protease inhibitors/1
(Sigma-Aldrich)]. Western blotting analysis was performed us-
ing 70 lg of protein extracts and filters were blotted with anti-
bodies against gp91phox (Nox2; 1:300, BD Transduction
Laboratories), Nrf2 (1:1000, Santa Cruz Biotechnology) and
GAPDH (1:1000, Santa Cruz Biotechnology). Signals derived from
appropriate HRP-conjugated secondary antibodies (Bethyl
Laboratories, Montgomery, TX, USA) were captured by Chemi
DocTM XRS 2015 (Bio-Rad Laboratories, Hercules, CA, USA) and
densitometric analysis was performed using Image Lab soft-
ware (Version 5.2.1;VC Bio-Rad Laboratories).
GSH and GSSG analyses
GSH and GSSG levels were detected in muscle and whole blood
using the enzymatic re-cycling assay (59), with minor modifica-
tions. Briefly, samples were de-proteinized with 5% (w/v) sul-
phosalicylic acid (SSA, Sigma-Aldrich) and the glutathione
content was determined after dilution of the acid-soluble frac-
tion in Na-phosphate buffer containing EDTA (pH 7.5). To pre-
vent an overestimation of GSSG due to oxidation of thiols
during sample manipulation, blood samples were collected in
tubes prefilled with 30 mM NEM. GSH and GSSG concentrations
were measured with ThioStarVR glutathione detection reagent
(Arbor Assays, Michigan, USA), using respectively GSH and
GSSG as standards (Sigma Chemicals, St. Louis, MO, USA). The
fluorescence was measured using an EnSpireVR Multimode Plate
Reader (Perkin Elmer, Waltham, MA, USA).
Figure 6. Scheme representing the relationship between the Nrf2-signaling
pathway and inflammation in DMD. The dystrophin deficiency induces Nrf2 ac-
tivation to counteract NOX2-triggered oxidative stress. Nevertheless, low levels
of HO-1 together with high IL-6 concentrations weaken the efficacy of the anti-
oxidant compensatory mechanism and promote the establishment of a chronic
inflammation, which ultimately exacerbates the dystrophic phenotype.
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GPx assay
GPx activity was measured in whole blood samples by spectro-
photometric assay using the Glutathione Peroxidase Assay Kit
(Cayman Chemical Company, Ann Arbor, MI, USA), according to
the manufacturer’s instructions. GPx activities were determined
following NADPH oxidation at 340 nm and using cumene hydro-
peroxide as substrate.
Carbonylated protein
Plasma protein carbonyls were assayed according to the proto-
col provided by the manufacturer (Cayman Chemicals, MI,
USA). Protein concentrations (mg/ml) were measured using
Pierce BCA (Thermo Scientific). Carbonyl concentrations were
expressed as nmol/mg protein.
Data analysis and statistics
Statistical analysis was performed using the GRAPHPAD/Prism
5.0 Software (SanDiego, CA, USA). Statistically significant differ-
ences between groups were analyzed using Student’s t-test for
normally distributed variables. All data are presented as
mean6 standard deviation or as mean6 standard error of the
mean (SEM). Statistical significance was defined as *P< 0.05,
**P< 0.01, ***P< 0.001, compared with healthy controls and
#P< 0.05, ##P< 0.01, ###P< 0.001 between classes. Statistical dif-
ferences among animal groups were assessed using one-way
analysis of variance (ANOVA) with a Bonferroni post-test or
Student’s t-test.
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